Diallyl Trisulfide (H2S donor) 二烯丙基三硫
產品編號 | 產品名稱 | 包裝規格 | 價格 |
NBS5893-25mg | Diallyl Trisulfide (H2S donor) 二烯丙基三硫 | 25mg | 654 |
NBS5893-100mg | Diallyl Trisulfide (H2S donor) 二烯丙基三硫 | 100mg | 2366 |
【溫馨提示】:見我司整理的硫化氫(H2S)熒光探針產品專題—WSP-1/WSP-5/AzMC。
產品簡介:
二烯丙基三硫(Diallyl Trisulfide, DATS)是一種大蒜中發現的有機多硫化物,用作一種天然的硫化氫(H2S)供體。DATS能夠減少前列腺癌細胞PC-3的存活率(IC50=22 μM)和抑制人結腸腺癌細胞HCT15的生長(IC50=11.5μM)。體內,DATS阻抑前列腺癌PC-3細胞裸鼠移植瘤生長,誘導血管平滑肌松弛。
產品特性:
CAS NO.:2050-87-5
化學名:di-2-propen-1-yl trisulfide
同義名:DATS; NSC 651936;二烯丙基三硫醚;二烯丙基三硫化物;
分子式:C6H10S3
分子量:178.34
外觀:液體
純度:≥95%
溶解性:溶于DMSO(≥10mg/ml)、乙醇(≥5mg/ml)、不溶于水
化學結構圖:
保存條件:
-20oC保存,至少1年穩定。
產品使用:【源自文獻,僅作參考】
文獻1:
體外研究(In Vitro Assay):
細胞類型(Cell type):BGC-823 and GSE-1 cell
實驗方法(Cell viability assay):The sulforhodamine B (SRB) assay was performed as described to measure BGC-823 and GSE-1 cell viability after DATS treatment. Briefly, 3.0×103 cells/well were grown in 96-well plates for 12 h and exposed todifferent concentrations of DATS (0–400 μmol/L) for 24 or 48 h.
體內研究(In Vivo Assay):
動物模型(Animal Model):Tumor xenograft mice model
實驗方法(Assay):To establish gastric carcinoma xenograft tumors in mice, BGC-823 cells (5.0×106) were suspended in 100 μL PBS and subcutaneously injected into the mice. The mice were sacrificed a month later. The tumor was separated by 2 mm fragments and implanted into other mice. When tumor volumes reached approximately 100 mm3,mice were randomized and assigned to the following treatments: control (normal saline, containing 20% β-cycloamylose, every day); cisplatin (5 mg/kg, positive control, every 5 d); treated groups (DATS was formed with β-cycloamylose and dissolved in normal saline, dosage at 20, 30 or 40 mg·kg?1·d?1); and the co-treated group (cisplatin, 5 mg/kg every 5 d and DATS at 30 mg/kg all other days). All mice were sacrificed on the 32nd day,and the tumors were excised for weight measurement and histopathological analysis.
文獻2:
體內研究(In Vivo Assay):
動物模型(Animal Model):Tumor xenograft mice model
配制方法(Formulation):DATS was maintained in sealed amber glass ampules and kept at?20°C until use. On the day of experimentation, a fresh glass ampule of DATS was opened. DATS (5μl) was diluted in 500 μl of 100% DMSO. For in vivo experiments, the DATS in 100% DMSO solution was further diluted in sterile saline to obtain the correct dosage to be delivered in a volume of 50 μl. The resulting concentration of DMSO in this dosage was 1%. Vehicle consisted of a solution of 1% DMSO in sterile saline.
實驗方法(Assay):DATS was administered at 200 μg/kg before reperfusion by either an intravenous injection 5 min before reperfusion or an intraperitoneal injection 22.5 min before reperfusion.After 24 h of reperfusion, the LV area at risk (AAR) and infarct size were determined by Evan's blue and 2,3,5-tetrazolium chloride staining, as previously described.
注意事項:
1. 本品并非商業化的臨床藥物,僅用作科研用途,不得用作臨床診斷或治療,不得用于食品或藥品,絕對禁止用在人身上。
2. 為了您的安全和健康,請穿實驗服并戴一次性手套操作。
相關產品:
產品編號 | 產品名稱 | 包裝規格 |
1mg | ||
1mg | ||
1mg | ||
10mg | ||
1mg | ||
1mg | ||
1mg | ||
1mg | ||
1mg | ||
1mg | ||
5mg | ||
50mg | ||
250mg | ||
DL-Propargylglycine (PAG) (hydrochloride) DL-炔丙基甘氨酸鹽酸鹽(CSE抑制劑) | 250mg |